Close Menu

NEW YORK (GenomeWeb) – PreCyte has received a one-year, $300,000 grant from the National Cancer Institute to develop a blood-based lung cancer diagnostic based on its core Indicator Cell Assay Platform (ICAP) technology.

ICAP was originally developed at the Institute for Systems Biology in the lab of company Co-founder John Aitchison and involves the use of cultured cells as biosensors, exposing them to patient serum and analyzing the transcriptional effect.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A Harvard University professor has been charged with making false claims regarding funds he received from China, the New York Times reports.

Discover magazine reports that animal dissections might dissuade students from science careers, but that a firm has developed synthetic frogs for dissections.

Nature News reports that a US panel is reviewing current guidelines for federally funded gain-of-function viral research.

In PNAS this week: de novo mutation patterns among the Amish, an alternative RNA-seq method, and more.